Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2022 | May 10, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2022 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q1 | |
Trading Symbol | ALT | |
Entity Registrant Name | ALTIMMUNE, INC. | |
Entity Central Index Key | 0001326190 | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 43,219,358 | |
Entity Interactive Data Current | Yes | |
Title of 12(b) Security | Common stock, par value $0.0001 per share | |
Security Exchange Name | NASDAQ | |
Entity File Number | 001-32587 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 20-2726770 | |
Entity Address, Address Line One | 910 Clopper Road | |
Entity Address, Address Line Two | Suite 201S | |
Entity Address, City or Town | Gaithersburg | |
Entity Address, State or Province | MD | |
Entity Address, Postal Zip Code | 20878 | |
City Area Code | 240 | |
Local Phone Number | 654-1450 | |
Document Transition Report | false |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 179,947 | $ 190,301 |
Restricted cash | 34 | 34 |
Total cash, cash equivalents and restricted cash | 179,981 | 190,335 |
Accounts receivable | 193 | 429 |
Income tax and R&D incentive receivables | 5,880 | 5,410 |
Prepaid expenses and other current assets | 5,039 | 7,952 |
Total current assets | 191,093 | 204,126 |
Property and equipment, net | 1,337 | 1,448 |
Intangible assets, net | 12,419 | 12,419 |
Other assets | 811 | 872 |
Total assets | 205,660 | 218,865 |
Current liabilities: | ||
Accounts payable | 2,205 | 2,034 |
Contingent consideration | 4,310 | 6,090 |
Accrued expenses and other current liabilities | 12,609 | 10,152 |
Total current liabilities | 19,124 | 18,276 |
Other long-term liabilities | 1,668 | 1,454 |
Total liabilities | 20,792 | 19,730 |
Commitments and contingencies (Note 16) | ||
Stockholders' equity: | ||
Common stock, $0.0001 par value; 200,000,000 shares authorized; 43,219,896 and 40,993,768 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively | 4 | 4 |
Additional paid-in capital | 502,505 | 497,342 |
Accumulated deficit | (312,601) | (293,171) |
Accumulated other comprehensive loss, net | (5,040) | (5,040) |
Total stockholders' equity | 184,868 | 199,135 |
Total liabilities and stockholders' equity | $ 205,660 | $ 218,865 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares | Mar. 31, 2022 | Dec. 31, 2021 |
CONSOLIDATED BALANCE SHEETS | ||
Common stock, par or stated value per share | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 200,000,000 | 200,000,000 |
Common stock, shares issued | 43,219,896 | 40,993,768 |
Common stock, shares outstanding | 43,219,896 | 40,993,768 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||
Revenues | $ 32 | $ 838 |
Operating expenses: | ||
Research and development | 15,104 | 11,878 |
General and administrative | 4,427 | 3,821 |
Total operating expenses | 19,531 | 15,699 |
Loss from operations | (19,499) | (14,861) |
Other income (expense): | ||
Interest expense | (62) | (12) |
Interest income | 21 | 42 |
Other income (expense), net | 110 | (33) |
Total other income (expense), net | 69 | (3) |
Net loss | (19,430) | (14,864) |
Other comprehensive income - unrealized gain on short-term investments | 5 | |
Comprehensive loss | $ (19,430) | $ (14,859) |
Net loss per share, basic | $ (0.44) | $ (0.38) |
Net loss per share, diluted | $ (0.44) | $ (0.38) |
Weighted-average common shares outstanding, basic | 43,969,481 | 38,914,990 |
Weighted-average common shares outstanding, diluted | 43,969,481 | 38,914,990 |
CONSOLIDATED STATEMENTS OF CHAN
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands | Common Stock [Member] | Additional Paid-In Capital [Member] | Accumulated Deficit [Member] | Accumulated Other Comprehensive Loss [Member] | Total |
Beginning Balance at Dec. 31, 2020 | $ 4 | $ 417,337 | $ (186,421) | $ (5,044) | $ 225,876 |
Beginning Balance (in shares) at Dec. 31, 2020 | 37,142,946 | ||||
Stock-based compensation | 1,218 | 1,218 | |||
Vesting of restricted stock awards including withholding, net | (92) | (92) | |||
Vesting of restricted stock awards including withholding, net (in shares) | (6,349) | ||||
Issuance of common stock from Employee Stock Purchase Plan | 106 | 106 | |||
Issuance of common stock from Employee Stock Purchase Plan (in shares) | 8,733 | ||||
Issuance of common stock in at the market offerings, net | 34,178 | 34,178 | |||
Issuance of common stock in at the market offerings, net (in shares) | 2,110,800 | ||||
Retirement of common stock in exchange for common stock warrant | (7,540) | (9,660) | (17,200) | ||
Retirement of common stock in exchange for common stock warrant (in Shares) | (1,000,000) | ||||
Issuance of common stock warrant in exchange for retirement of common stock | 17,200 | 17,200 | |||
Issuance of common stock upon cashless exercise of warrants | 10 | 10 | |||
Issuance of common stock upon cashless exercise of warrants (in shares) | 1,050 | ||||
Other comprehensive income - unrealized gain on short-term investments | 5 | 5 | |||
Net loss | (14,864) | (14,864) | |||
Ending Balance at Mar. 31, 2021 | $ 4 | 462,417 | (210,945) | (5,039) | 246,437 |
Ending Balance (in shares) at Mar. 31, 2021 | 38,257,180 | ||||
Beginning Balance at Dec. 31, 2021 | $ 4 | 497,342 | (293,171) | (5,040) | 199,135 |
Beginning Balance (in shares) at Dec. 31, 2021 | 40,993,768 | ||||
Stock-based compensation | 2,033 | 2,033 | |||
Exercise of stock options | 197 | 197 | |||
Exercise of stock options (in shares) | 95,771 | ||||
Vesting of restricted stock awards including withholding, net | (170) | (170) | |||
Vesting of restricted stock awards including withholding, net (in shares) | 17,568 | ||||
Issuance of common stock from Employee Stock Purchase Plan | 113 | 113 | |||
Issuance of common stock from Employee Stock Purchase Plan (in shares) | 16,450 | ||||
Issuance of common stock in at the market offerings, net | 2,990 | 2,990 | |||
Issuance of common stock in at the market offerings, net (in shares) | 335,485 | ||||
Issuance of common stock upon cashless exercise of warrants (in shares) | 1,760,854 | ||||
Net loss | (19,430) | (19,430) | |||
Ending Balance at Mar. 31, 2022 | $ 4 | $ 502,505 | $ (312,601) | $ (5,040) | $ 184,868 |
Ending Balance (in shares) at Mar. 31, 2022 | 43,219,896 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net loss | $ (19,430) | $ (14,864) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Change in fair value of contingent consideration liability | (1,780) | 880 |
Stock-based compensation expense | 2,033 | 1,218 |
Depreciation and amortization | 119 | 74 |
Unrealized (gains) losses on foreign currency exchange | (110) | 33 |
Changes in operating assets and liabilities: | ||
Accounts receivable | 236 | (191) |
Prepaid expenses and other current assets | 3,046 | (4,201) |
Accounts payable | 171 | (194) |
Accrued expenses and other liabilities | 2,659 | (2,189) |
Income tax and R&D incentive receivables | (470) | (135) |
Net cash used in operating activities | (13,526) | (19,569) |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Proceeds from sales and maturities of short-term investments | 30,912 | |
Purchases of short-term investments | (7,476) | |
Purchases of property and equipment, net | (9) | (4,209) |
Cash paid for internally developed patents | (62) | |
Net cash (used in) provided by investing activities | (9) | 19,165 |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Payments of deferred offering costs | (119) | 135 |
Proceeds from issuance of common stock in at-the-market offerings, net | 2,990 | 34,178 |
Proceeds from issuance of common stock from Employee Stock Purchase Plan | 113 | 106 |
Proceeds from exercises of stock options | 197 | |
Net cash provided by financing activities | 3,181 | 34,419 |
Net (decrease) increase in cash and cash equivalents and restricted cash | (10,354) | 34,015 |
Cash, cash equivalents and restricted cash at beginning of period | 190,335 | 115,952 |
Cash, cash equivalents and restricted cash at end of period | $ 179,981 | 149,967 |
SUPPLEMENTAL NON-CASH ACTIVITIES: | ||
Fair value of common stock retired in exchange for issuance of common stock warrant | $ 17,200 |
Nature of Business and Basis of
Nature of Business and Basis of Presentation | 3 Months Ended |
Mar. 31, 2022 | |
Nature of Business and Basis of Presentation | |
Nature of Business and Basis of Presentation | 1. Nature of Business and Basis of Presentation Nature of Business Altimmune, Inc., headquartered in Gaithersburg, Maryland, United States, together with its subsidiaries (collectively, the “Company” or “Altimmune”) is a clinical stage biopharmaceutical company incorporated under the laws of the State of Delaware. The Company is focused on developing treatments for obesity and liver diseases. The Company’s pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (“NASH”) (for both, pemvidutide [proposed INN], formerly known as ALT-801), and for chronic hepatitis B (HepTcell). Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff and raising capital, and has financed its operations through the issuance of common and preferred stock, long-term debt and proceeds from research grants and government contracts. The Company has not generated any revenues from the sale of any products to date, and there is no assurance of any future revenues from product sales. Basis of Presentation The accompanying unaudited consolidated financial statements are prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States (“U.S. GAAP”) for complete consolidated financial statements and should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2021 included in the Annual Report on Form 10-K which was filed with the SEC on March 15, 2022. In the opinion of management, the Company has prepared the accompanying unaudited consolidated financial statements on the same basis as the audited consolidated financial statements, and these consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results of the interim periods presented. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year 2022 or any future years or periods. The accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should we be unable to continue as a going concern. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2022 | |
Summary of Significant Accounting Policies | |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies During the three months ended March 31, 2022, there have been no significant changes to the Company’s summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC. Use of Estimates The preparation of these financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The extent to which the COVID-19 pandemic, including any resurgences or the emergence of new variants, may directly or indirectly impact the Company’s business, financial condition, and results of operations is highly uncertain and subject to change. The Company considered the potential impact of the COVID-19 pandemic on the Company’s estimates and assumptions and determined that there was not a material impact to the Company’s unaudited consolidated financial statements as of and for the three months ended March 31, 2022. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods. |
Fair Value Measurements
Fair Value Measurements | 3 Months Ended |
Mar. 31, 2022 | |
Fair Value Measurements | |
Fair Value Measurements | 3. Fair Value Measurements The Company’s assets and liabilities measured at fair value on a recurring basis at March 31, 2022 consisted of the following (in thousands): Fair Value Measurement at March 31, 2022 Total Level 1 Level 2 Level 3 Assets: Cash equivalents - money market funds $ 65,641 $ 65,641 $ — $ — Total 65,641 65,641 — — Liabilities: Contingent consideration liability (see Note 8) 4,310 — — 4,310 Total $ 4,310 $ — $ — $ 4,310 The Company’s assets and liabilities measured at fair value on a recurring basis at December 31, 2021 consisted of the following (in thousands): Fair Value Measurement at December 31, 2021 Total Level 1 Level 2 Level 3 Assets: Cash equivalents - money market funds $ 65,634 $ 65,634 $ — $ — Total 65,634 65,634 — — Liabilities: Contingent consideration liability (see Note 8) 6,090 — — 6,090 Total $ 6,090 $ — $ — $ 6,090 The fair value of contingent payments classified as a liability is based on the regulatory milestones described in Note 8 and estimated using the Monte Carlo simulation valuation model with Level 3 inputs. The assumptions used to estimate the fair value of contingent payments that are classified as a liability at March 31, 2022 include the following significant unobservable inputs: Unobservable input Value or Range Weighted-Average Expected volatility 84.4% 84.4% Risk-free interest rate 0.90% 0.90% Cost of capital 30% 30% Discount for lack of marketability 10%‑13% 12% Probability of payment 94% 94% Projected year of payment 2022 2022 If applicable, the Company will recognize transfers into and out of Level 3 within the fair value hierarchy at the end of the reporting period in which the actual event or change in circumstance occurs. There were no transfers into or out of Level 3 of the fair value hierarchy as of March 31, 2022 and December 31, 2021. Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. Assets recorded at fair value on a non-recurring basis, such as property and equipment and intangible assets are recognized at fair value when they are impaired. During the three months ended March 31, 2022, the Company had no significant assets or liabilities that were measured at fair value on a non-recurring basis. During the year ended December 31, 2021, the Company recorded non-cash impairment charges to property and equipment, net on a non-recurring basis (see below). Lonza Manufacturing Agreement In March 2021, the Company expanded its manufacturing collaboration with Lonza Houston, Inc. (“Lonza”) for the manufacture of AdCOVID or other adenovirus-based vaccines. Under the expanded agreement, the Company had committed approximately $23.0 million to Lonza to procure long-lead equipment and construct a dedicated manufacturing suite for clinical and commercial production of adenovirus-based vaccines. This work was completed during the fourth quarter of 2021. The Company capitalized a total of $4.0 million as construction-in-progress (“CIP”) during the three months ended March 31, 2021 under this expanded agreement. The Company subsequently terminated the agreement and impaired the amount during the year ended December 31, 2021. |
Property and Equipment, Net
Property and Equipment, Net | 3 Months Ended |
Mar. 31, 2022 | |
Property and Equipment, Net | |
Property and Equipment, Net | 4. Property and Equipment, Net Property and equipment, net consists of the following (in thousands): March 31, 2022 December 31, 2021 Furniture, fixtures and equipment $ 163 $ 222 Laboratory equipment 243 1,040 Computers and telecommunications 179 291 Software 128 148 Leasehold improvements 1,749 1,794 Property and equipment, at cost 2,462 3,495 Less: accumulated depreciation and amortization (1,125) (2,047) Property and equipment, net $ 1,337 $ 1,448 Depreciation expense related to property and equipment was approximately $0.1 million for both the three months ended March 31, 2022 and 2021. |
Intangible Assets
Intangible Assets | 3 Months Ended |
Mar. 31, 2022 | |
Intangible Assets | |
Intangible Assets | 5. Intangible Assets The Company’s intangible assets consist of the following (in thousands): March 31, 2022 Gross Estimated Carrying Accumulated Net Book Useful Lives Value Amortization Impairment Value IPR&D assets Indefinite $ 12,419 $ — $ — $ 12,419 Total $ 12,419 $ — $ — $ 12,419 December 31, 2021 Gross Estimated Carrying Accumulated Net Book Useful Lives Value Amortization Impairment Value Internally developed patents 6 $ 1,079 $ (500) $ (579) $ — Acquired licenses 16 285 (285) — — Total intangible assets subject to amortization 1,364 (785) (579) — IPR&D assets Indefinite 12,419 — — 12,419 Total $ 13,783 $ (785) $ (579) $ 12,419 There was no amortization expense of intangible assets subject to amortization for the three months ended March 31, 2022. Amortization expense of intangible assets subject to amortization totalled $6,640 for the three months ended March 31, 2021. Amortization expense was classified as research and development expenses in the consolidated statements of operations and comprehensive loss. There was no in-process research and development (“IPR&D”) impairment loss during the three months ended March 31, 2022 and the year ended December 31, 2021. |
Operating Leases
Operating Leases | 3 Months Ended |
Mar. 31, 2022 | |
Operating Leases | |
Operating Leases | 6. Operating Leases The Company rents office and laboratory space in the United States. The Company also leases office equipment under non-cancellable equipment leases through June 2026. Rent expense during the three months ended March 31, 2022 and 2021 under all of the Company’s operating leases was $0.1 million and $0.1 million, respectively. Rent expense includes short-term leases and variable lease costs that are not included in the lease obligation. Short-term leases are leases having a term of twelve months or less. The Company recognizes short-term leases on a straight-line basis and does not record a related lease asset or liability for such leases. The office space leases provide for increases in future minimum annual rental payments as defined in the lease agreements. The office space lease also includes an option to renew the lease as of the end of the term. The Company has determined that the lease renewal option is not reasonably certain of being exercised. The cash paid for operating lease liabilities for both the three months ended March 31, 2022 and 2021 was $0.1 million. Supplemental other information related to the operating leases balance sheet information is as follows (in thousands, except lease term and discount rate): March 31, 2022 December 31, 2021 Operating lease obligations (see Note 7 and 9) $ 1,437 $ 1,535 Operating lease right-of-use assets (included in "Other assets" in Balance Sheet) $ 750 $ 798 Weighted-average remaining lease term (years) 3.1 3.3 Weighted-average discount rate 7.2 % 7.2 % |
Accrued Expenses
Accrued Expenses | 3 Months Ended |
Mar. 31, 2022 | |
Accrued Expenses | |
Accrued Expenses | 7. Accrued Expenses Accrued expenses and other current liabilities consist of the following (in thousands): March 31, 2022 December 31, 2021 Accrued professional services $ 642 $ 396 Accrued payroll and employee benefits 1,117 2,313 Accrued research and development 10,382 6,988 Lease obligation, current portion (see Note 6) 421 411 Accrued interest and other 47 44 Total accrued expenses and other current liabilities $ 12,609 $ 10,152 |
Contingent Consideration
Contingent Consideration | 3 Months Ended |
Mar. 31, 2022 | |
Contingent Consideration | |
Contingent consideration | 8. Contingent Consideration The Company entered into an Agreement and Plan of Merger and Reorganization, dated July 8, 2019, by and among the Company, Springfield Merger Sub, Inc., Springfield Merger Sub, LLC, Spitfire Pharma, Inc. and David Collier, as the Stockholder Representative (the “Spitfire Merger Agreement”) to acquire all of the equity interests of Spitfire Pharma, Inc. (“Spitfire”). Spitfire was a privately held, preclinical pharmaceutical company developing a novel dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis. The transaction closed on July 12, 2019. The Company issued 1,887,250 unregistered shares of its common stock as upfront consideration to certain former securityholders of Spitfire (collectively, the “Spitfire Equityholders”), representing an amount equal to $5.0 million less working capital and transaction expense adjustment amounts as defined in the agreement. The acquisition of Spitfire was accounted for as an asset acquisition instead of a business combination because substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset or group of similar identifiable assets, and therefore, the asset was not considered a business. The Company expensed the acquired intellectual property as of the acquisition date as in-process research and development with no alternative future uses. The Spitfire Merger Agreement also includes future contingent payments up to $88.0 million in cash and shares of the Company’s common stock as follows (each, a “Milestone Event”): ● a one-time payment of $5.0 million (the “IND Milestone Consideration Amount”) within sixty days of the submission of an Investigational New Drug Application (“IND”) to the United States Food and Drug Administration (the “FDA”) or other applicable governmental authority in a foreign jurisdiction, which IND has not been rejected or placed on clinical hold by the FDA or such applicable foreign governmental authority within time specified in the Merger Agreement; ● a one-time payment of $3.0 million (the “Phase 2 Milestone Consideration Amount” and together with the IND Milestone Consideration Amount, the “Regulatory Milestones”) within sixty days of the initiation (first patient, first dosing) of a Phase 2 clinical trial of a product candidate anywhere in the world; and ● payments of up to $80.0 million upon the achievement of specified worldwide net sales (the “Sales Milestones”) of all products developed using the technology acquired in the License Agreement within ten years following the approval of a new drug application filed with the FDA. The Regulatory Milestones will be payable in shares of the Company’s Common Stock, with the number of shares of the Company’s Common Stock to be issued in connection with each milestone amount, if any, are dependent on the share price at the time of achievement. The number of any shares issued in consideration for the IND Milestone Consideration Amount will be determined based on lower of (A) the average of the closing prices of our Common Stock as reported on the Nasdaq Global Market for the twenty twenty The future contingent payments related to the Regulatory Milestones are stock-based payments accounted for under FASB Accounting Standards Codification Topic 480, Distinguishing Liabilities From Equity Contingencies On November 3, 2020, the Company received acknowledgement from the Australian Government Department of Health on the Company’s submitted clinical trial notification (“CTN”) which triggered the obligation to settle the IND Milestone payment to the former owners. As a result, on November 19, 2020, the Company issued 1,694,906 shares of its Common Stock valued at $9.57 per share for the amount value of $13.6 million to the former Spitfire stockholders. Pursuant to the Spitfire Merger Agreement, the Company issued the shares within sixty days of the submission of the CTN, which was October 29, 2020. From September 30, 2020 through November 19, 2020, the date of issuance, the Company recognized a decrease in the fair value of the IND Milestone payment of $5.4 million to research and development expense and reclassified the balance in the contingent consideration liability associated with the fair value of the IND Milestone payment to equity in the Company’s consolidated balance sheet. No Regulatory Milestones were achieved during the three months ended March 31, 2022. The Phase 2 Milestone was met on April 26, 2022. See Note 17 for further details. The Company estimates the future contingent consideration for the Regulatory Milestones based upon a Monte Carlo simulation valuation model that is risk adjusted based on the probability of achieving the milestones and a discount for lack of marketability. The Company remeasures the fair value of the contingent consideration at each reporting period. During the fourth quarter of 2020, the Company achieved the IND Milestone and paid the obligation in shares according to the calculation above. Below is a summary of the contingent consideration activity (in thousands): Three Months Ended March 31, 2022 2021 Beginning balance $ 6,090 $ 5,390 Change in fair value (1,780) 880 Ending balance $ 4,310 $ 6,270 As of March 31, 2022, the decrease in fair value was primarily attributable to a decrease in the closing share price of the Company’s common stock, partially offset by an increase in the probability of milestone achievement. As of March 31, 2021, the increase in fair value was primarily attributable to an increase in the closing share price of the Company’s common stock and in the probability of milestone achievement. Any changes in fair value have been recorded within research and development expense during the respective periods presented. |
Other Long-Term Liabilities
Other Long-Term Liabilities | 3 Months Ended |
Mar. 31, 2022 | |
Other Long-Term Liabilities | |
Other Long-Term Liabilities | 9. Other Long-Term Liabilities The Company’s other long-term liabilities are summarized as follows (in thousands): March 31, 2022 December 31, 2021 Lease obligation, long-term portion (see Note 6) $ 1,016 $ 1,124 Conditional economic incentive grants 250 250 Other 402 80 Total other long-term liabilities $ 1,668 $ 1,454 |
Common Stock
Common Stock | 3 Months Ended |
Mar. 31, 2022 | |
Common Stock | |
Common Stock | 10. Common Stock Public Offering On July 16, 2020, the Company offered and sold (i) 3,369,564 shares of common stock, at a price to the public of $23.00 per share, and (ii) pre-funded warrants of the Company to purchase 1,630,436 shares of common stock at an exercise price equal to $0.0001 per share (the “Pre-Funded Warrants”), at a price to the public of $22.9999 per share of common stock underlying the Pre-Funded Warrants (equal to the public offering price per share of Common Stock, minus the exercise price of each Pre-Funded Warrant). The Pre-Funded Warrants are exercisable at any time, provided that each Pre-Funded Warrant holder will be prohibited from exercising such Pre-Funded Warrants into shares of the Company’s common stock if, as a result of such exercise, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of the Company’s common stock then issued and outstanding, which percentage may change at the holders’ election to any other number less than or equal to 19.99% upon 61 days’ notice to the Company. The gross proceeds of this offering were approximately $132.2 million, which includes the exercise in full of the underwriters’ option to purchase an additional 750,000 shares of common stock, before deducting underwriting discounts and commissions and offering expenses during the third quarter of 2020. The net proceeds of this offering were approximately $124.0 million, after deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company has assessed the Pre-Funded Warrants for appropriate equity or liability classification and determined that the Pre-Funded Warrants are freestanding instruments that do not meet the definition of a liability pursuant to ASC 480 and do not meet the definition of a derivative pursuant to FASB Accounting Standards Codification Topic 815, Derivatives and Hedging At-the-Market Offerings On February 25, 2021, the Company entered into an Equity Distribution Agreement (the “2021 Agreement”) with Piper Sandler & Co., Evercore Group L.L.C. and B. Riley Securities, Inc., serving as sales agents (the “Sales Agents”) with respect to an at-the-market offerings program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $125.0 million (the “Shares”) through the Sale Agents (the “2021 Offering”). Any Shares offered and sold in the 2021 Offering will be issued pursuant to the Company’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission (the “SEC”) on December 31, 2020, which was declared effective on January 11, 2021, the prospectus supplement relating to the 2021 Offering filed with the SEC on February 25, 2021 and any applicable additional prospectus supplements related to the 2021 Offering that form a part of the Registration Statement. During the three months ended March 31, 2022, the Company sold 335,485 shares of Common Stock under the 2021 Agreement resulting in approximately $3.0 million in net proceeds. As of March 31, 2022, the Company has sold in aggregate 5,135,939 shares of Common Stock under the 2021 Agreement resulting in approximately $67.8 million in net proceeds, with $55.0 million remaining available to be sold under the 2021 Agreement. As of March 31, 2022, the Company recorded approximately $0.1 million of offering costs which offset the proceeds received from the shares sold through March 31, 2022. The Company capitalized approximately $0.1 million of deferred offering costs which will offset future proceeds received under the 2021 Agreement. Exchange Agreement On February 25, 2021, the Company entered into an exchange agreement (the “Exchange Agreement”) with an Investor and its affiliates (the “Exchanging Stockholders”), pursuant to which the Company exchanged an aggregate of 1,000,000 shares of the Company’s common stock, par value $0.0001 per share, owned by the Exchanging Stockholders for pre-funded warrants (the “Exchange Warrants”) to purchase an aggregate of 1,000,000 shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $0.0001 per share. The Exchange Warrants did not have an expiration date and were exercisable at any time except that the Exchange Warrants could not be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would beneficially own more than 9.99% of the Company’s common stock, subject to certain exceptions. In accordance with FASB Accounting Standards Codification Topic 505, Equity |
Warrants
Warrants | 3 Months Ended |
Mar. 31, 2022 | |
Warrants | |
Warrants | 11. Warrants A summary of warrant activity during the three months ended March 31, 2022 is as follows: Warrants outstanding, December 31, 2021 2,776,191 Exercises (see Note 10) (1,760,870) Warrants outstanding, March 31, 2022 1,015,321 |
Stock-Based Compensation
Stock-Based Compensation | 3 Months Ended |
Mar. 31, 2022 | |
Stock-Based Compensation | |
Stock-Based Compensation | 12. Stock-Based Compensation Stock Options The Company’s stock option awards generally vest over four years and typically have a contractual life of ten years. At March 31, 2022, there was $14.0 million of unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted-average period of 3.1 years. During the three months ended March 31, 2022, the Company granted 1,020,427 stock options with a weighted average exercise price of $6.91 and per share weighted average grant date fair value of $6.06. Information related to stock options outstanding at March 31, 2022 is as follows (in thousands, except share, exercise price and contractual term): Weighted-Average Weighted- Remaining Number of Average Contractual Term Aggregate Intrinsic Stock Options Exercise Price (Years) Value Outstanding 3,464,793 $ 8.41 6.0 $ 4,045 Exercisable 1,271,282 $ 7.45 5.8 $ 2,759 Unvested 2,193,511 $ 8.96 6.0 $ 1,286 Restricted Stock At March 31, 2022, the Company had unvested restricted stock of 53,818 shares with total unrecognized compensation expense of $0.2 million, which the Company expects to recognize over a weighted average period of approximately 0.7 years. During the three months ended March 31, 2022, the Company released 20,182 shares of unrestricted common stock as a result of the vesting of restricted stock. Restricted Stock Units During the three months ended March 31, 2022, the Company granted 255,000 shares of restricted stock units which vest over four years. At March 31, 2022, the Company had unvested restricted stock units of 446,837 shares with total unrecognized compensation expense of $3.9 million, which the Company expects to recognize over a weighted average period of approximately 3.5 years. During the three months ended March 31, 2022, the Company released 40,091 shares of unrestricted common stock as a result of the vesting of restricted stock units. 2019 Employee Stock Purchase Plan Under the Employee Stock Purchase Plan, employees purchased 16,450 shares for $0.1 million during the three months ended March 31, 2022. During the three months ended March 31, 2022, the Company recognized compensation expense of $0.1 million. Stock-based Compensation Expense Stock-based compensation expense is classified in the unaudited consolidated statements of operations and comprehensive loss for the three months ended March 31, 2022 and 2021 as follows (in thousands): For the Three Months Ended March 31, 2022 2021 Research and development $ 618 $ 321 General and administrative 1,415 897 Total $ 2,033 $ 1,218 |
U.S. Government Contracts and G
U.S. Government Contracts and Grants | 3 Months Ended |
Mar. 31, 2022 | |
U.S. Government Contracts and Grants | |
U.S. Government Contracts and Grants | 13. U.S. Government Contracts and Grants In June 2020, the Company was awarded $4.7 million from the U.S. Army Medical Research & Development Command (“USAMRDC”) to fund its Phase 1/2 clinical trial of T-COVID. The competitive award was granted by USAMRDC in collaboration with the Medical Technology Enterprise Consortium (“MTEC”), a 501(c)(3) biomedical technology consortium working in partnership with the Department of Defense (“DoD”). Under the contract, MTEC paid the Company a firm fixed fee based upon the achievement of certain milestones for conduct and completion of a Phase 1/2 study and research and development work on the replication-deficient adenovirus 5 (“RD-Ad5”) vector vaccine platform. For the three months ended March 31, 2021, the Company recognized approximately $0.5 million of grant revenue under the contract, which completed the full recognition of this award. No revenue was recognized for this contract for the three months ended March 31, 2022. In July 2016, the Company signed a five-year contract with Biomedical Advanced Research and Development Authority (“BARDA”). The contract, as amended, had a total value of up to $136.8 million to be used to fund clinical development of NasoShield. Under the contract, BARDA paid the Company a fixed fee and reimbursed certain costs for the research and development of an Ad5-vectored, protective antigen-based intranasal anthrax vaccine through cGMP manufacture and conduct of a Phase 1 clinical trial dose ranging assessment of safety and immunogenicity. The contract consisted of an initial base performance period providing approximately $30.9 million in funding for the period July 2016 through December 2021. BARDA had seven options to extend the contract to fund certain continued development and manufacturing activities for the anthrax vaccine, including Phase 2 clinical studies. Each option, if exercised by BARDA, would have provided additional funding ranging from approximately $1.1 million to $34.4 million for a three-year period beginning in 2021. For the three months ended March 31, 2021, the Company recognized approximately $0.2 million of grant revenue under the BARDA contract. For the three months ended March 31, 2022, the Company has recognized de minimis grant revenue related to the close-out of the BARDA contract. BARDA did not extend the contract beyond the end of December 2021. |
Income Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2022 | |
Income Taxes | |
Income Taxes | 14. Income Taxes Due to a full valuation allowance, the Company did not record an income tax benefit for both the three months ended March 31, 2022 and 2021. |
Net Loss Per Share
Net Loss Per Share | 3 Months Ended |
Mar. 31, 2022 | |
Net Loss Per Share | |
Net Loss Per Share | 15. Net Loss Per Share Because the Company has reported a net loss attributable to common stockholders for all periods presented, basic and diluted net loss per share attributable to common stockholders are the same for all periods presented. Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average numbers of shares of common stock outstanding for the period. Basic shares outstanding includes the weighted average effect of the Company’s outstanding pre-funded warrants, the exercise of which requires little or no consideration for the delivery of shares of common stock. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period. As such, all unvested restricted stock, restricted stock units, common stock warrants, and stock options have been excluded from the computation of diluted weighted average shares outstanding because such securities would have an anti-dilutive impact for all periods presented. Potential common shares issuable upon conversion, vesting or exercise of unvested restricted stock, restricted stock units, common stock warrants, and stock options that are excluded from the computation of diluted weighted-average shares outstanding, as they are anti-dilutive, are as follows: For the Three Months Ended March 31, 2022 2021 Common stock warrants 145,755 145,755 Common stock options 3,479,992 2,307,264 Restricted stock units 446,837 196,279 Restricted stock 53,818 134,545 |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2022 | |
Commitments And Contingencies. | |
Commitments and Contingencies | 16. Commitments and Contingencies Spitfire Acquisition As disclosed in Note 8, the Company is obligated to make payments of up to $80.0 million upon the achievement of specified worldwide net sales of all products developed using the technology acquired from Spitfire Pharma Inc. within ten years following the approval of a new drug application filed with the FDA. Litigation In December 2019, a complaint was filed by Dr. De-Chu Christopher Tang (“Plaintiff”) against the Company, which was removed to the United States District Court for the Eastern District of Texas. The Plaintiff amended the complaint in February 2020 to include Vipin K. Garg and David J. Drutz as defendants, in addition to the Company (Dr. Garg, Dr. Drutz, and the Company are collectively referred to as “Defendants”). In March 2020 the Defendants filed a motion to dismiss the complaint. The Court denied the motion without prejudice and allowed Plaintiff an opportunity to file an amended complaint. Plaintiff’s second amended complaint was filed on April 17, 2020, and Defendants filed a motion to dismiss that complaint on May 1, 2020. A hearing on Defendants’ motion to dismiss was held on May 20, 2020. Plaintiff, who is representing himself, alleges five causes of action as follows: (1) Defendants’ alleged retention of Plaintiff’s lab notebooks after the termination of his employment in 2012; (2) alleged plagiarism based on publishing an article without naming Plaintiff as an author; (3) use of the Adhigh System, which Plaintiff alleges he developed; (4) allegations that Defendants manipulated our stock and caused a decrease in value; and (5) allegations that the Defendants “wast[ed] government grant money and poison[ed] science by leaving data to rot.” On September 30, 2020, Plaintiff filed a motion titled “Motion to Proscribe Defendants’ Allegedly Illegal Use of Plaintiff’s AdHigh System in Altimmune’s Human Clinical Trials,” to which Defendants filed an opposition on October 13, 2020. The court has not yet ruled on that motion, which also remains pending. On November 6, 2020, Defendants filed a motion for summary judgment on the basis of lack of personal jurisdiction, insufficient service of process, and failure to state a claim. The court ruled on that motion on March 25, 2021, which dismissed the case on the basis of lack of personal jurisdiction. On December 1, 2020, the magistrate judge assigned to the case issued a report and recommendation that Defendants’ motion to dismiss of May 1, 2020 be granted and that this action be dismissed for lack of personal jurisdiction. Plaintiff filed objections to the report and recommendation on December 14, 2020, and the resolution of those objections by the district court remains pending. In December 2021, the Plaintiff refiled the complaint in the United States District Court for the District of Maryland. On February 24, 2022, Defendants filed a memorandum containing a brief description of the planned motion and a concise summary of the factual and legal support for it. On the basis of that memorandum, the Court granted Defendants’ request to file a motion to dismiss and allowed Plaintiff an opportunity to file an amended complaint. Plaintiff’s amended complaint was filed on March 3, 2022, and Defendants filed a motion to dismiss that complaint on April 4, 2022. The Company believes the allegations in the complaint are without merit and intends to vigorously defend the litigation. The Company is a party in various contracts and subject to disputes, litigation, and potential claims arising in the ordinary course of business, none of which are currently reasonably possible or probable of material loss. |
Subsequent Events
Subsequent Events | 3 Months Ended |
Mar. 31, 2022 | |
Subsequent Events | |
Subsequent Events | 17. Subsequent Events Contingent Consideration On April 26, 2022, the Company dosed the first patient in the Phase 2 MOMENTUM trial of pemvidutide in obesity, which triggered the obligation to pay the Phase 2 Milestone Consideration Amount to the Spitfire Equityholders. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2022 | |
Summary of Significant Accounting Policies | |
Use of Estimates | Use of Estimates The preparation of these financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The extent to which the COVID-19 pandemic, including any resurgences or the emergence of new variants, may directly or indirectly impact the Company’s business, financial condition, and results of operations is highly uncertain and subject to change. The Company considered the potential impact of the COVID-19 pandemic on the Company’s estimates and assumptions and determined that there was not a material impact to the Company’s unaudited consolidated financial statements as of and for the three months ended March 31, 2022. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods. |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Fair Value Measurements | |
Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis | The Company’s assets and liabilities measured at fair value on a recurring basis at March 31, 2022 consisted of the following (in thousands): Fair Value Measurement at March 31, 2022 Total Level 1 Level 2 Level 3 Assets: Cash equivalents - money market funds $ 65,641 $ 65,641 $ — $ — Total 65,641 65,641 — — Liabilities: Contingent consideration liability (see Note 8) 4,310 — — 4,310 Total $ 4,310 $ — $ — $ 4,310 The Company’s assets and liabilities measured at fair value on a recurring basis at December 31, 2021 consisted of the following (in thousands): Fair Value Measurement at December 31, 2021 Total Level 1 Level 2 Level 3 Assets: Cash equivalents - money market funds $ 65,634 $ 65,634 $ — $ — Total 65,634 65,634 — — Liabilities: Contingent consideration liability (see Note 8) 6,090 — — 6,090 Total $ 6,090 $ — $ — $ 6,090 |
Summary of Assumptions Used to Estimate Fair Value of Contingent Payments | The assumptions used to estimate the fair value of contingent payments that are classified as a liability at March 31, 2022 include the following significant unobservable inputs: Unobservable input Value or Range Weighted-Average Expected volatility 84.4% 84.4% Risk-free interest rate 0.90% 0.90% Cost of capital 30% 30% Discount for lack of marketability 10%‑13% 12% Probability of payment 94% 94% Projected year of payment 2022 2022 |
Property and Equipment, Net (Ta
Property and Equipment, Net (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Property and Equipment, Net | |
Summary of Property and Equipment, Net | Property and equipment, net consists of the following (in thousands): March 31, 2022 December 31, 2021 Furniture, fixtures and equipment $ 163 $ 222 Laboratory equipment 243 1,040 Computers and telecommunications 179 291 Software 128 148 Leasehold improvements 1,749 1,794 Property and equipment, at cost 2,462 3,495 Less: accumulated depreciation and amortization (1,125) (2,047) Property and equipment, net $ 1,337 $ 1,448 |
Intangible Assets (Tables)
Intangible Assets (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Intangible Assets | |
Schedule of Intangible Assets | The Company’s intangible assets consist of the following (in thousands): March 31, 2022 Gross Estimated Carrying Accumulated Net Book Useful Lives Value Amortization Impairment Value IPR&D assets Indefinite $ 12,419 $ — $ — $ 12,419 Total $ 12,419 $ — $ — $ 12,419 December 31, 2021 Gross Estimated Carrying Accumulated Net Book Useful Lives Value Amortization Impairment Value Internally developed patents 6 $ 1,079 $ (500) $ (579) $ — Acquired licenses 16 285 (285) — — Total intangible assets subject to amortization 1,364 (785) (579) — IPR&D assets Indefinite 12,419 — — 12,419 Total $ 13,783 $ (785) $ (579) $ 12,419 |
Operating Leases (Tables)
Operating Leases (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Operating Leases | |
Summary of Supplemental other Information Related to Operating Leases Balance Sheet | Supplemental other information related to the operating leases balance sheet information is as follows (in thousands, except lease term and discount rate): March 31, 2022 December 31, 2021 Operating lease obligations (see Note 7 and 9) $ 1,437 $ 1,535 Operating lease right-of-use assets (included in "Other assets" in Balance Sheet) $ 750 $ 798 Weighted-average remaining lease term (years) 3.1 3.3 Weighted-average discount rate 7.2 % 7.2 % |
Accrued Expenses (Tables)
Accrued Expenses (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Accrued Expenses | |
Schedule of Accrued Expenses and Other Current Liabilities | Accrued expenses and other current liabilities consist of the following (in thousands): March 31, 2022 December 31, 2021 Accrued professional services $ 642 $ 396 Accrued payroll and employee benefits 1,117 2,313 Accrued research and development 10,382 6,988 Lease obligation, current portion (see Note 6) 421 411 Accrued interest and other 47 44 Total accrued expenses and other current liabilities $ 12,609 $ 10,152 |
Contingent Consideration (Table
Contingent Consideration (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Contingent Consideration | |
Summary of Fair Value of Contingent Consideration | Below is a summary of the contingent consideration activity (in thousands): Three Months Ended March 31, 2022 2021 Beginning balance $ 6,090 $ 5,390 Change in fair value (1,780) 880 Ending balance $ 4,310 $ 6,270 |
Other Long-Term Liabilities (Ta
Other Long-Term Liabilities (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Other Long-Term Liabilities | |
Summary of Other Long-Term Liabilities | The Company’s other long-term liabilities are summarized as follows (in thousands): March 31, 2022 December 31, 2021 Lease obligation, long-term portion (see Note 6) $ 1,016 $ 1,124 Conditional economic incentive grants 250 250 Other 402 80 Total other long-term liabilities $ 1,668 $ 1,454 |
Warrants (Tables)
Warrants (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Warrants | |
Summary of Warrant Activity | A summary of warrant activity during the three months ended March 31, 2022 is as follows: Warrants outstanding, December 31, 2021 2,776,191 Exercises (see Note 10) (1,760,870) Warrants outstanding, March 31, 2022 1,015,321 |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Stock-Based Compensation | |
Schedule of Information Related to Stock Options Outstanding | Information related to stock options outstanding at March 31, 2022 is as follows (in thousands, except share, exercise price and contractual term): Weighted-Average Weighted- Remaining Number of Average Contractual Term Aggregate Intrinsic Stock Options Exercise Price (Years) Value Outstanding 3,464,793 $ 8.41 6.0 $ 4,045 Exercisable 1,271,282 $ 7.45 5.8 $ 2,759 Unvested 2,193,511 $ 8.96 6.0 $ 1,286 |
Schedule of Stock-based Compensation Expense | Stock-based compensation expense is classified in the unaudited consolidated statements of operations and comprehensive loss for the three months ended March 31, 2022 and 2021 as follows (in thousands): For the Three Months Ended March 31, 2022 2021 Research and development $ 618 $ 321 General and administrative 1,415 897 Total $ 2,033 $ 1,218 |
Net Loss Per Share (Tables)
Net Loss Per Share (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Net Loss Per Share | |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | Potential common shares issuable upon conversion, vesting or exercise of unvested restricted stock, restricted stock units, common stock warrants, and stock options that are excluded from the computation of diluted weighted-average shares outstanding, as they are anti-dilutive, are as follows: For the Three Months Ended March 31, 2022 2021 Common stock warrants 145,755 145,755 Common stock options 3,479,992 2,307,264 Restricted stock units 446,837 196,279 Restricted stock 53,818 134,545 |
Fair Value Measurements - Sched
Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 | Mar. 31, 2021 | Dec. 31, 2020 |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||||
Contingent consideration liability (see Note 8) | $ 4,310 | $ 6,090 | $ 6,270 | $ 5,390 |
Fair Value, Measurements, Recurring [Member] | ||||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||||
Total | 65,641 | 65,634 | ||
Contingent consideration liability (see Note 8) | 4,310 | 6,090 | ||
Total | 4,310 | 6,090 | ||
Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | ||||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||||
Total | 65,641 | 65,634 | ||
Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | ||||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||||
Contingent consideration liability (see Note 8) | 4,310 | 6,090 | ||
Total | 4,310 | 6,090 | ||
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | ||||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||||
Cash equivalents | 65,641 | 65,634 | ||
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | ||||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||||
Cash equivalents | $ 65,641 | $ 65,634 |
Fair Value Measurements - Summa
Fair Value Measurements - Summary of Assumptions Used to Estimate Fair Value of Contingent Payments (Detail) - Level 3 [Member] | 3 Months Ended |
Mar. 31, 2022 | |
Expected Volatility [Member] | |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | |
Assumptions used to estimate fair value of contingent payments | 84.4 |
Risk-free Interest Rate [Member] | |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | |
Assumptions used to estimate fair value of contingent payments | 0.90 |
Cost of Capital [Member] | |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | |
Assumptions used to estimate fair value of contingent payments | 30 |
Probability of Payment [Member] | |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | |
Assumptions used to estimate fair value of contingent payments | 94 |
Projected Year of Payment [Member] | |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | |
Assumptions used to estimate fair value of contingent payments | 2022 |
Minimum [Member] | Discount for Lack of Marketability [Member] | |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | |
Assumptions used to estimate fair value of contingent payments | 10 |
Maximum [Member] | Discount for Lack of Marketability [Member] | |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | |
Assumptions used to estimate fair value of contingent payments | 13 |
Weighted Average [Member] | Expected Volatility [Member] | |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | |
Assumptions used to estimate fair value of contingent payments | 84.4 |
Weighted Average [Member] | Risk-free Interest Rate [Member] | |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | |
Assumptions used to estimate fair value of contingent payments | 0.90 |
Weighted Average [Member] | Cost of Capital [Member] | |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | |
Assumptions used to estimate fair value of contingent payments | 30 |
Weighted Average [Member] | Discount for Lack of Marketability [Member] | |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | |
Assumptions used to estimate fair value of contingent payments | 12 |
Weighted Average [Member] | Probability of Payment [Member] | |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | |
Assumptions used to estimate fair value of contingent payments | 94 |
Weighted Average [Member] | Projected Year of Payment [Member] | |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | |
Assumptions used to estimate fair value of contingent payments | 2022 |
Fair Value Measurements - Addit
Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended |
Mar. 31, 2021 | Mar. 31, 2022 | Dec. 31, 2021 | |
Fair value transfers into Level 3 | $ 0 | $ 0 | |
Fair value transfers out of Level 3 | 0 | $ 0 | |
Assets or liabilities measured at fair value on a non-recurring basis. | $ 0 | ||
CIP related assets | $ 4 | ||
Lonza Manufacturing Agreement [Member] | |||
Commitment to procure equipment and construction | $ 23 |
Property and Equipment, Net - S
Property and Equipment, Net - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Property Plant And Equipment [Line Items] | ||
Property and equipment, at cost | $ 2,462 | $ 3,495 |
Less: accumulated depreciation and amortization | (1,125) | (2,047) |
Property and equipment, net | 1,337 | 1,448 |
Furniture, Fixtures and Equipment [Member] | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, at cost | 163 | 222 |
Laboratory Equipment [Member] | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, at cost | 243 | 1,040 |
Computers and Telecommunications [Member] | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, at cost | 179 | 291 |
Software [Member] | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, at cost | 128 | 148 |
Leasehold Improvements | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, at cost | $ 1,749 | $ 1,794 |
Property and Equipment, Net - A
Property and Equipment, Net - Additional Information (Detail) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Property and Equipment, Net | ||
Depreciation | $ 0.1 | $ 0.1 |
Intangible Assets - Schedule of
Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Mar. 31, 2022 | |
Schedule Of Intangible Assets [Line Items] | ||
Intangible assets subject to amortization, Gross Carrying Value | $ 1,364 | |
Intangible assets subject to amortization, Accumulated Amortization | (785) | |
Total intangible assets, Gross Carrying Value | 13,783 | $ 12,419 |
Total intangible assets, Impairment | (579) | |
Total intangible assets, Net Book Value | 12,419 | 12,419 |
IPR&D [Member] | ||
Schedule Of Intangible Assets [Line Items] | ||
Total intangible assets, Gross Carrying Value | 12,419 | 12,419 |
Total intangible assets, Net Book Value | 12,419 | $ 12,419 |
Internally Developed Patents [Member] | ||
Schedule Of Intangible Assets [Line Items] | ||
Intangible assets subject to amortization, Gross Carrying Value | 1,079 | |
Intangible assets subject to amortization, Accumulated Amortization | (500) | |
Total intangible assets, Impairment | $ (579) | |
Internally Developed Patents [Member] | Minimum [Member] | ||
Schedule Of Intangible Assets [Line Items] | ||
Estimated Useful Lives | 6 years | |
Internally Developed Patents [Member] | Maximum [Member] | ||
Schedule Of Intangible Assets [Line Items] | ||
Estimated Useful Lives | 20 years | |
Acquired Licenses [Member] | ||
Schedule Of Intangible Assets [Line Items] | ||
Intangible assets subject to amortization, Gross Carrying Value | $ 285 | |
Intangible assets subject to amortization, Accumulated Amortization | $ (285) | |
Acquired Licenses [Member] | Minimum [Member] | ||
Schedule Of Intangible Assets [Line Items] | ||
Estimated Useful Lives | 16 years | |
Acquired Licenses [Member] | Maximum [Member] | ||
Schedule Of Intangible Assets [Line Items] | ||
Estimated Useful Lives | 20 years |
Intangible Assets - Additional
Intangible Assets - Additional Information (Detail) - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | |
Schedule Of Intangible Assets [Line Items] | |||
Impairment loss on intangible assets | $ 579,000 | ||
IPR&D [Member] | |||
Schedule Of Intangible Assets [Line Items] | |||
Impairment charge | $ 0 | $ 0 | |
Research and Development [Member] | |||
Schedule Of Intangible Assets [Line Items] | |||
Amortization expense of intangible assets | $ 0 | $ 6,640 |
Operating Leases - Additional I
Operating Leases - Additional Information (Detail) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Operating Leases | ||
Non-cancellable lease maturity period | 2026-06 | |
Cash paid for operating lease liabilities | $ 0.1 | $ 0.1 |
Operating lease rent expense | $ 0.1 | $ 0.1 |
Operating Leases - Summary of S
Operating Leases - Summary of Supplemental other Information Related to Operating Leases Balance Sheet (Detail) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Operating Leases | ||
Operating lease obligations (see Note 7 and 9) | $ 1,437 | $ 1,535 |
Operating lease right-of-use assets (included in "Other assets" in Balance Sheet) | $ 750 | $ 798 |
Weighted-average remaining lease term (years) | 3 years 1 month 6 days | 3 years 3 months 18 days |
Weighted-average discount rate | 7.20% | 7.20% |
Accrued Expenses - Schedule of
Accrued Expenses - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Accrued Liabilities And Other Liabilities [Abstract] | ||
Accrued professional services | $ 642 | $ 396 |
Accrued payroll and employee benefits | 1,117 | 2,313 |
Accrued research and development | 10,382 | 6,988 |
Lease obligation, current portion (see Note 6) | 421 | 411 |
Accrued interest and other | 47 | 44 |
Total accrued expenses and other current liabilities | $ 12,609 | $ 10,152 |
Contingent Consideration - Addi
Contingent Consideration - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands | Nov. 19, 2020 | Jul. 12, 2019 | Nov. 19, 2020 | Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 |
Business Acquisition [Line Items] | |||||||
Estimated future contingent consideration | $ 4,310 | $ 6,270 | $ 6,090 | $ 5,390 | |||
Change in value of contingent consideration for acquired in-process research and development | $ (1,780) | $ 880 | |||||
Regulatory milestone achieved | 0 | ||||||
Clinical Trial Notification [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Up-front consideration | $ 13,600 | ||||||
Shares issued for contingent milestone payment | 1,694,906 | ||||||
Period for submission of clinical trial notification | 60 days | ||||||
Submission date of clinical trial notification | Oct. 29, 2020 | ||||||
Clinical Trial Notification [Member] | Regulatory Milestones [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Change in value of contingent consideration for acquired in-process research and development | $ 5,400 | ||||||
Spitfire Pharma, Inc. [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Agreement date | Jul. 8, 2019 | ||||||
Unregistered shares of common stock | 1,887,250 | ||||||
Up-front consideration | $ 5,000 | ||||||
Spitfire Pharma, Inc. [Member] | Investigational New Drug Application Milestone [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Estimated future contingent consideration | $ 5,000 | ||||||
Estimated future contingent consideration term | 60 days | ||||||
Number of consecutive trading days | 20 days | ||||||
Consideration amount | $ 2.95 | ||||||
Spitfire Pharma, Inc. [Member] | Investigational New Drug Application and Regulatory Milestones [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Estimated future contingent consideration | $ 3,000 | ||||||
Estimated future contingent consideration term | 60 days | ||||||
Number of consecutive trading days | 20 days | ||||||
Consideration amount | $ 3.54 | ||||||
Spitfire Pharma, Inc. [Member] | Sales Milestones [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Estimated future contingent consideration | $ 80,000 | ||||||
License agreement term | 10 years | ||||||
Spitfire Pharma, Inc. [Member] | Regulatory Milestones [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Upfront consideration release at 3 months | 50.00% | ||||||
Upfront consideration release at 9 months | 50.00% | ||||||
Spitfire Pharma, Inc. [Member] | Clinical Trial Notification [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Consideration amount | $ 9.57 | $ 9.57 | |||||
Spitfire Pharma, Inc. [Member] | Common Stock [Member] | Maximum [Member] | |||||||
Business Acquisition [Line Items] | |||||||
Estimated future contingent consideration | $ 88,000 |
Contingent Consideration - Summ
Contingent Consideration - Summary of Fair Value of Contingent Consideration (Detail) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Contingent Consideration | ||
Beginning balance | $ 6,090 | $ 5,390 |
Change in fair value of contingent consideration liability | (1,780) | 880 |
Ending balance | $ 4,310 | $ 6,270 |
Other Long-Term Liabilities - S
Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Detail) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Other Long-Term Liabilities | ||
Lease obligation, long-term portion (see Note 6) | $ 1,016 | $ 1,124 |
Conditional economic incentive grants | 250 | 250 |
Other | 402 | 80 |
Total other long-term liabilities | $ 1,668 | $ 1,454 |
Common Stock - Additional Infor
Common Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands | Feb. 25, 2021 | Jul. 16, 2020 | Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 |
Changes In Equity And Comprehensive Income Line Items [Line Items] | |||||
Proceeds from issuance of common stock in public offering, net | $ 2,990 | $ 34,178 | |||
Common stock, par or stated value per share | $ 0.0001 | $ 0.0001 | |||
Pre-Funded Warrants [Member] | |||||
Changes In Equity And Comprehensive Income Line Items [Line Items] | |||||
Number of securities called by warrants or rights | 760,870 | ||||
Pre-funded Warrants Remaining to Exercise | 869,566 | ||||
Common Stock [Member] | |||||
Changes In Equity And Comprehensive Income Line Items [Line Items] | |||||
Shares of common stock sold | 335,485 | 2,110,800 | |||
Exchange Warrants [Member] | |||||
Changes In Equity And Comprehensive Income Line Items [Line Items] | |||||
Shares of common stock sold | 999,984 | ||||
Number of securities called by warrants or rights | 1,000,000 | ||||
Exercise price of warrants or rights | $ 0.0001 | ||||
Common stock, par or stated value per share | $ 0.0001 | ||||
Common stock exchanged for pre-funded warrants | 1,000,000 | ||||
Number of warrants exercised | 1,000,000 | ||||
Ownership percentage | 9.99% | ||||
Public Offering [Member] | |||||
Changes In Equity And Comprehensive Income Line Items [Line Items] | |||||
Gross proceeds from offering including exercise of underwriter's option | $ 132,200 | ||||
Public Offering [Member] | Pre-Funded Warrants [Member] | |||||
Changes In Equity And Comprehensive Income Line Items [Line Items] | |||||
Exercise price of warrants or rights | $ 0.0001 | ||||
Purchase price of warrants issued | $ 22.9999 | ||||
Ownership percentage on exercise of warrants without notice, minimum | 4.99% | ||||
Ownership percentage on exercise of warrants with notice, maximum | 19.99% | ||||
Notice period to increase ownership percentage on exercise of warrants | 61 days | ||||
Public Offering [Member] | Common Stock [Member] | |||||
Changes In Equity And Comprehensive Income Line Items [Line Items] | |||||
Shares of common stock sold | 3,369,564 | ||||
Public offering price, per share | $ 23 | ||||
Public Offering [Member] | Common Stock [Member] | Pre-Funded Warrants [Member] | |||||
Changes In Equity And Comprehensive Income Line Items [Line Items] | |||||
Number of securities called by warrants or rights | 1,630,436 | ||||
Over-Allotment Option [Member] | Common Stock [Member] | |||||
Changes In Equity And Comprehensive Income Line Items [Line Items] | |||||
Shares of common stock sold | 750,000 | ||||
Proceeds from issuance of common stock in public offering, net | $ 124,000 | ||||
At-The-Market Offering [Member] | |||||
Changes In Equity And Comprehensive Income Line Items [Line Items] | |||||
Shares of common stock sold | 335,485 | ||||
Proceeds from issuance of common stock in public offering, net | $ 3,000 | ||||
At-The-Market Offering [Member] | Equity Distribution Agreement [Member] | Piper Sandler company and evercore group limited liability company and B Riley Securities inc [Member] | |||||
Changes In Equity And Comprehensive Income Line Items [Line Items] | |||||
Shares of common stock sold | 5,135,939 | ||||
Proceeds from issuance of common stock in public offering, net | $ 67,800 | ||||
Common stock, par or stated value per share | $ 0.0001 | ||||
Aggregate offering price | $ 125,000 | ||||
Common stock available to be sold | 55,000 | ||||
Deferred offering costs | 100 | ||||
Issuance costs | $ 100 |
Warrants - Summary of Warrant A
Warrants - Summary of Warrant Activity (Detail) | 3 Months Ended |
Mar. 31, 2022shares | |
Warrants | |
Warrants outstanding, December 31, 2021 | 2,776,191 |
Exercises (see Note 10) | (1,760,870) |
Warrants outstanding, March 31, 2022 | 1,015,321 |
Stock-Based Compensation - Addi
Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Employees purchased, value | $ 113 | $ 106 |
Stock-based compensation expense | $ 2,033 | $ 1,218 |
2019 Employee Stock Purchase Plan [Member] | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Employees purchased, shares | 16,450 | |
Employees purchased, value | $ 100 | |
Stock-based compensation expense | $ 100 | |
Stock Options [Member] | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Vesting Period | 4 years | |
Stock option expiration Period | 10 years | |
Unrecognized compensation cost, stock options | $ 14,000 | |
Unrecognized stock-based compensation expense, period for recognition | 3 years 1 month 6 days | |
Number of Stock Options, Granted | 1,020,427 | |
Stock options granted, weighted-average exercise price | $ 6.91 | |
Weighted-average grant date fair value of stock options granted | $ 6.06 | |
Restricted Stock [Member] | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Unrecognized stock-based compensation expense, period for recognition | 8 months 12 days | |
Unvested restricted stock, shares | 53,818 | |
Unrecognized compensation expense | $ 200 | |
Common stock issued as result of vesting of restricted stock | 20,182 | |
Restricted Stock Units [Member] | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Vesting Period | 4 years | |
Unrecognized stock-based compensation expense, period for recognition | 3 years 6 months | |
Unvested restricted stock, shares | 446,837 | |
Unrecognized compensation expense | $ 3,900 | |
Common stock issued as result of vesting of restricted stock | 40,091 | |
Shares granted | 255,000 |
Stock-Based Compensation - Sche
Stock-Based Compensation - Schedule of Information Related to Stock Options Outstanding (Detail) | 3 Months Ended |
Mar. 31, 2022USD ($)$ / sharesshares | |
Stock-Based Compensation | |
Number of Stock Options, Outstanding | shares | 3,464,793 |
Number of Stock Options, Exercisable | shares | 1,271,282 |
Number of Stock Options, Unvested | shares | 2,193,511 |
Weighted-average Exercise Price, Outstanding | $ / shares | $ 8.41 |
Weighted-average Exercise Price, Exercisable | $ / shares | 7.45 |
Weighted-average Exercise Price, Unvested | $ / shares | $ 8.96 |
Weighted-average Remaining Contractual Term, Outstanding | 6 years |
Weighted-average Remaining Contractual Term, Exercisable | 5 years 9 months 18 days |
Weighted-average Remaining Contractual Term, Unvested | 6 years |
Aggregate Intrinsic Value, Outstanding | $ | $ 4,045 |
Aggregate Intrinsic Value, Exercisable | $ | 2,759 |
Aggregate Intrinsic Value, Unvested | $ | $ 1,286 |
Stock-Based Compensation - Sc_2
Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Detail) - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||
Stock based compensation expense | $ 2,033 | $ 1,218 |
Research and Development [Member] | ||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||
Stock based compensation expense | 618 | 321 |
General and Administrative [Member] | ||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||
Stock based compensation expense | $ 1,415 | $ 897 |
U.S. Government Contracts and_2
U.S. Government Contracts and Grants - Additional Information (Detail) - USD ($) $ in Thousands | Jan. 01, 2021 | Jun. 30, 2020 | Jul. 31, 2016 | Mar. 31, 2022 | Mar. 31, 2021 |
Revenues | $ 32 | $ 838 | |||
BARDA Contract [Member] | |||||
Duration of contract | 3 years | 5 years | |||
Amount used to fund clinical development | $ 136,800 | ||||
BARDA Contract [Member] | Minimum [Member] | |||||
Additional funding for development and manufacturing activities | $ 1,100 | ||||
BARDA Contract [Member] | Maximum [Member] | |||||
Additional funding for development and manufacturing activities | $ 34,400 | ||||
MTEC Collaborative Arrangement [Member] | |||||
Revenues | $ 4,700 | ||||
Grant [Member] | BARDA Contract [Member] | |||||
Revenues | 200 | ||||
Grant [Member] | MTEC Collaborative Arrangement [Member] | |||||
Revenues | $ 0 | $ 500 | |||
Investment Performance [Member] | BARDA Contract [Member] | |||||
Revenues | $ 30,900 |
Net Loss Per Share - Schedule o
Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Common Stock Warrants [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share | 145,755 | 145,755 |
Stock Options [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share | 3,479,992 | 2,307,264 |
Restricted Stock [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share | 53,818 | 134,545 |
Restricted Stock Units [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share | 446,837 | 196,279 |
Commitments and Contingencies -
Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Thousands | Jul. 12, 2019 | Mar. 31, 2022 | Dec. 31, 2021 | Mar. 31, 2021 | Dec. 31, 2020 |
Commitments And Contingencies [Line Items] | |||||
Estimated future contingent consideration | $ 4,310 | $ 6,090 | $ 6,270 | $ 5,390 | |
Spitfire Pharma, Inc. [Member] | Sales Milestones [Member] | |||||
Commitments And Contingencies [Line Items] | |||||
Estimated future contingent consideration | $ 80,000 | ||||
License agreement term | 10 years |